Iovance Biotherapeutics Inc IOVA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/10/24 EDT
11.07quote price arrow up+0.11 (+0.96%)
Volume
308,598
Close
10.96quote price arrow down-2.48 (-18.48%)
Volume
18,770,348
52 week range
3.21 - 18.33
Loading...
  • Open13.04
  • Day High13.19
  • Day Low10.70
  • Prev Close13.45
  • 52 Week High18.33
  • 52 Week High Date02/28/24
  • 52 Week Low3.21
  • 52 Week Low Date10/19/23

Key Stats

  • Market Cap3.068B
  • Shares Out279.83M
  • 10 Day Average Volume4.35M
  • Dividend-
  • Dividend Yield-
  • Beta0.88
  • YTD % Change34.87

KEY STATS

  • Open13.04
  • Day High13.19
  • Day Low10.70
  • Prev Close13.45
  • 52 Week High18.33
  • 52 Week High Date02/28/24
  • 52 Week Low3.21
  • 52 Week Low Date10/19/23
  • Market Cap3.068B
  • Shares Out279.83M
  • 10 Day Average Volume4.35M
  • Dividend-
  • Dividend Yield-
  • Beta0.88
  • YTD % Change34.87

RATIOS/PROFITABILITY

  • EPS (TTM)-1.81
  • P/E (TTM)-6.05
  • Fwd P/E (NTM)-8.36
  • EBITDA (TTM)-439.055M
  • ROE (TTM)-81.91%
  • Revenue (TTM)1.189M
  • Gross Margin (TTM)-804.54%
  • Net Margin (TTM)-37,345.42%
  • Debt To Equity (MRQ)0.17%

EVENTS

  • Earnings Date08/06/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Iovance Biotherapeutics Inc

 

Profile

MORE
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF...
Iain Dukes Ph.D.
Independent Chairman of the Board
Frederick Vogt J.D., Ph.D.
Interim President, Interim Chief Executive Officer, General Counsel, Corporate Secretary
Igor Bilinsky Ph.D.
Chief Operating Officer
Jean-Marc Bellemin
Chief Financial Officer
Address
825 INDUSTRIAL ROAD, 4TH FLOOR
San Carlos, CA
94070
United States

Top Peers

SYMBOLLASTCHG%CHG
CRNX
Crinetics Pharmaceuticals Inc
48.00-1.42-2.87%
BHVN
Biohaven Ltd
35.69-5.67-13.71%
SWTX
SpringWorks Therapeutics Inc
40.89-2.06-4.80%
JANX
Janux Therapeutics Inc
48.92-3.02-5.81%
XENE
Xenon Pharmaceuticals Inc
40.54-1.95-4.59%